





KidneyBleeding Complications After Percutaneous
Native Kidney Biopsy: Results From the Boston
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ogy, Brigham and Women’s Hospital, Boston, Massachusetts, USABackground: The major risk of kidney biopsy is severe bleeding. Numerous risk factors for bleeding after
biopsy have been reported, but findings have been inconsistent.
Methods: We retrospectively reviewed medical records of adult patients enrolled in a native kidney biopsy
cohort study to identify major bleeding events (red blood cell [RBC] transfusions, invasive procedures,
kidney loss, or death). We used logistic and linear regression models to identify characteristics associated
with postbiopsy RBC transfusions and decline in hemoglobin within a week after the procedure.
Results: Major bleeding events occurred in 28 of 644 (4.3%) patients (28 required an RBC transfusion, 4
underwent angiographic intervention, and 1 had open surgery to control bleeding). No patient lost a
kidney or died because of the biopsy. Postbiopsy RBC transfusion risk was driven by the baseline he-
moglobin level (odds ratio [OR] 13.6; 95% confidence interval [CI] 5.4–34.1 for hemoglobin <10 vs. $10
g/dl). After adjusting for hemoglobin, no other patient characteristics were independently associated with
RBC transfusions. Female sex (b ¼ 0.18; 95% CI: 0.04–0.32), estimated glomerular filtration rate (eGFR) <30
ml/min per 1.73 m2 (b ¼ 0.32; 95% CI: 0.14–0.49), and baseline hemoglobin (b ¼ 0.09; 95% CI: 0.05–0.13, per
g/dl increase) were independently associated with a larger drop in hemoglobin. Histopathologic lesions
were not independently associated with major bleeding after biopsy.
Conclusion: Biopsies were generally well tolerated. Baseline hemoglobin was the dominant risk factor for
RBC transfusions, but female sex and eGFR <30 ml/min per 1.73 m2 were also associated with a larger
decline in hemoglobin after the procedure.
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he kidney biopsy is a critical diagnostic and
prognostic tool for evaluation of patients with
kidney disease.1 Its results can guide management and
provide information on response to treatment.2 Due to
the high blood flow through the kidneys, which
receive approximately 20% of the cardiac output,3 the
major risks of kidney biopsies are related to bleeding.
Bleeding complications can range from self-limited
hematuria and asymptomatic perinephric hematomas
of minimal clinical significance to life-threatening
hemorrhage, resulting in hemodynamic instability,
kidney loss, and even death. In current practice,spondence: Sushrut S. Waikar, Section of Nephrology,
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International Reports (2020) 5, 511–518kidney biopsies are most commonly obtained percuta-
neously using real-time ultrasound guidance and
automatic spring-loaded biopsy devices, which have
been shown to decrease the risk of the procedure.4–7
The frequency of biopsy complications after percuta-
neous native kidney biopsies, however, varies across
studies, due to differences in patient populations and
procedural techniques, as well as variability in
complication definitions and the intensity of post-
procedural monitoring. Different studies have collec-
tively identified numerous risk factors for bleeding
complications following kidney biopsy, but findings
have been inconsistent.8 Associations of bleeding risk
with specific forms of kidney disease or histologic le-
sions have been reported sporadically, but generally
lack validation. We sought to further define the risk of
major bleeding complications after percutaneous native511
CLINICAL RESEARCH R Palsson et al.: Bleeding Complications After Kidney Biopsykidney biopsy and its associated clinical and pathologic
risk factors using a cohort of patients who underwent
biopsy at 2 academic hospitals in the northeast United
States.
METHODS
Study Design and Population
We retrospectively examined medical records of pa-
tients enrolled in the Boston Kidney Biopsy Cohort to
identify major biopsy-associated bleeding complica-
tions and gather data on covariates that had not been
collected as part of the original prospective design.
Details on the Boston Kidney Biopsy Cohort have been
described previously.9 For the current analysis, we
used data from adult ($18 years old) patients who
underwent clinically indicated percutaneous native
kidney biopsy at 2 of the participating academic hos-
pitals in Boston, Massachusetts, between September
2006 and June 2018. We included only the first biopsy
in the analysis if patients had more than 1 performed.
Procedures were performed either by a nephrologist or
interventional radiologist with use of imaging guidance
(either ultrasound or computed tomography) and
spring-loaded biopsy devices. Imaging was regularly
performed at the end of biopsy procedures to evaluate
for hematoma development, but subsequent imaging
was performed only as clinically indicated. Data were
stored using REDCap electronic data capture tools
hosted at Partners Healthcare.10 The study was
approved by the Partners Human Research Committee
(Institutional Review Board #2007P000003) and is in
accordance with the principles of the Declaration of
Helsinki.
Outcomes and Covariates
Data on biopsy-associated bleeding events were
collected by review of patient records. Outcomes of
interest included postbiopsy hematomas, RBC trans-
fusions, angiographic or open surgical interventions to
control bleeding, kidney loss, and death. Decline in
hemoglobin was also examined by recording the closest
hemoglobin level available up to 30 days before the
procedure and the lowest hemoglobin within 7 days
after biopsy.
Covariates examined included age, sex, race, base-
line laboratory tests (eGFR, prothrombin time, acti-
vated partial thromboplastin time, and proteinuria),
diagnosis of hypertension or diabetes mellitus, biopsy
indication, and the setting in which the procedure took
place (i.e., urgently in the inpatient setting vs.
following outpatient evaluation). Systolic blood pres-
sure was also examined, using the measurement most
proximal to the time of the biopsy. Histopathologic
lesions of interest, which included interstitial fibrosis512and tubular atrophy, global glomerulosclerosis, acute
tubular injury, and arterial and arteriolar sclerosis,
were semiquantitatively scored. Clinicopathologic di-
agnoses were adjudicated by reviewing biopsy reports
alongside patient medical records.
Statistical Analysis
We summarized continuous variables with means and
SDs if normally distributed and with medians and
interquartile ranges if not normally distributed and
performed group comparisons using t tests or Wil-
coxon rank sum tests, respectively. We summarized
count data as percentages and compared them between
groups using c2 or Fisher’s exact tests. We used
Spearman correlation coefficients to determine the as-
sociation between continuous variables.
In our primary analysis, we examined the associa-
tion of patient characteristics, selected a priori by re-
view of the literature and based on adequate
availability in the medical records, with the need for
RBC transfusion after biopsy. We first examined these
associations using univariable logistic regression
models and then analyzed them after adjusting for
prebiopsy hemoglobin levels, which we found to be
the most strongly associated characteristic. As bleeding
risk did not change linearly with the laboratory studies
in our analysis, they were dichotomized at thresholds
determined by examining the distribution of the data
among those who did versus did not receive an RBC
transfusion.
In a post hoc analysis, we explored the associations of
the same patient characteristics with decline in hemo-
globin using linear regression models. Each character-
istic of interest was initially examined in a univariable
model and all were subsequently entered together into
a multivariable model to identify variables indepen-
dently associated with hemoglobin decline. We also
used an automated stepwise selection procedure as a
secondary analysis to verify the characteristics most
strongly associated with postbiopsy hemoglobin
decline.
Regression analyses were initially conducted using
only cases with complete data (>90%). In sensitivity
analyses, the same models were examined after mul-
tiple imputation under multivariate normal distribu-
tion for missing data. In a separate sensitivity
analysis, an automated stepwise selection procedure
was used in a logistic regression model to identify
which of the clinical characteristics of interest were
most predictive of postbiopsy blood transfusion. Sta-
tistical tests were 2-sided, and we considered P <
0.05 as the threshold for significance. All statistical
analyses were performed using SAS version 9.4 (SAS
Institute Inc., Cary, NC).Kidney International Reports (2020) 5, 511–518















Hospital 1 (%) 4.2 95.8
Hospital 2 (%) 5.1 94.9
Age, yr 48.5 (35.1–64.8) 53.3 (37.2–66.3) 0.39 0
Female (%) 57.1 51.3 0.57 0




DM (%) 32.1 17.9 0.08 0
HTN (%) 50.0 49.0 0.92 0
SBP, mm Hg 132 (117–144) 130 (118–142) 0.74 4.2
ACE inhibitor or ARB (%) 32.1 43.3 0.33 0






21.3 (10.8–43.3) 45.6 (24.9–82.0) <0.01 0.1
eGFR >60 ml/min
per 1.73 m2 (%)
21.4 37.2 <0.01 0.1
30 < eGFR
# 60 ml/min
per 1.73 m2 (%)
14.3 31.2
eGFR # 30 ml/min
per 1.73 m2 (%)
64.3 31.6
Proteinuria, g/g Cr 1.30 (0.66–3.94) 1.47 (0.34–3.89) 0.48 1.6
Proteinuria
> 3.5 g/g Cr (%)
26.9% 28.6% 0.85
INR 1.1 (1.0–1.1) 1.0 (1.0–1.1) 0.02 2.3
INR $1.1 (%) 66.7 34.4 <0.01
aPTT 30.5 (27.6–33.6) 29.2 (26.7–31.8) 0.21 7.6








Reason for biopsy (%)a 0
Proteinuria 42.9 55.0 0.24
Hematuria 28.6 25.0 0.66
Worsening eGFR 64.3 34.1 <0.01
CT-guided instead of
US-guided biopsy (%)
3.6 10.2 0.34 0
Urgent inpatient
biopsy (%)
57.1 17.5 <0.01 0
ACE, angiotensin-converting enzyme; aPTT, activated partial thromboplastin time; ARB,
angiotensin II receptor blockers; Cr, creatinine; CT, computed tomography; DM, dia-
betes mellitus; eGFR, estimated glomerular filtration rate; HTN, hypertension; INR, in-
ternational normalized ratio; SBP, systolic blood pressure; US, ultrasound.
aReasons for biopsy are not mutually exclusive.
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The study cohort consisted of 644 individuals. The
median age was 53 years, 52% were female, and 65%
were white. The most commonly reported indications
for biopsy, which were not mutually exclusive, were
proteinuria (54.5%), worsening eGFR (35.4%), and
hematuria (25.2%). Computed tomography guidance
used to perform 9.9% of biopsies, whereas the
remainder were guided by ultrasound. Before biopsy,
the median (interquartile range) hemoglobin was 11.6
g/dl (10.1–13.3 g/dl), serum creatinine was 1.57 mg/dl
(0.98–2.48 mg/dl), eGFR was 44.9 ml/min per 1.73 m2
(23.4–81.6 ml/min per 1.73 m2), platelet count was 251
K/ml (201–315 K/ml), and international normalized ratio
(INR) was 1.0 (1.0–1.1) (Table 1).
The median decline in hemoglobin was 0.7 g/dl (0.3–
1.2 g/dl) or 6.2% (2.7%–10.6%); 39 patients had a
decline in hemoglobin >2 g/dl and 11 patients had a
decline >3 g/dl. Higher baseline hemoglobin was
weakly positively correlated with the absolute decline
in hemoglobin after biopsy (r ¼ 0.09, P ¼ 0.03). We
found baseline hemoglobin to be negatively correlated
with eGFR (r ¼ 0.50, P < 0.01), INR (r ¼ 0.34,
P < 0.01), and age (r ¼ 0.10, P ¼ 0.01). Median
(interquartile range) hemoglobin was lower among
women than men (11.2 g/dl [9.8–12.7 g/dl] vs. 12.2 g/dl
[10.2–14.0 g/dl], respectively, P < 0.01), among
patients with versus without diabetes (10.5 g/dl
[9.1–12.1 g/dl] vs. 11.9 g/dl [10.2–13.6 g/dl], respec-
tively, P < 0.01), among patients with worsening eGFR
as an indication for biopsy compared with those with
other indications (10.5 g/dl [9.2–12.2 g/dl] vs. 12.2 g/dl
[10.7–13.7 g/dl], respectively, P < 0.01), and among
patients undergoing urgent inpatient biopsies
compared with those whose biopsies were arranged
after outpatient evaluation (9.5 g/dl [8.7–10.4 g/dl] vs.
12.2 g/dl [10.7–13.6 g/dl], respectively, P < 0.01).
Hematomas were identified after biopsy in 29.0% of
cases, usually on immediate postprocedure imaging
(26.7%). Twenty-eight patients (4.3%) required RBC
transfusion postbiopsy. We found neither a significant
difference in transfusion rates between the 2 hospitals
(4.2% vs. 5.1%, P ¼ 0.76) nor a temporal trend during
the period of observation. Patients requiring transfusion
typically had lower baseline hemoglobin and eGFR
before the procedure, with 22 of 28 transfused patients
having a prebiopsy hemoglobin level<10 g/dl and 18 of
28 having an eGFR<30ml/min per 1.73 m2 (Figure 1). Of
the transfused patients, 4 (0.6% of the total cohort)
underwent angiography due to severe bleeding and 1
(0.2%) subsequently required surgical intervention
where a bleeding vessel was ligated. No patient lost a
kidney or died because of the biopsy (Figure 2).Kidney International Reports (2020) 5, 511–518Transfusion was required in 14.5% (95% CI: 9.4%–
21.4%) of patients with prebiopsy hemoglobin <10
g/dl compared with 1.2% (95% CI: 0.5%–2.8%) of
patients with prebiopsy hemoglobin $10 g/dl. Trans-
fusion was required in 8.5% (95% CI: 5.1%–13.1%) of
patients with an eGFR <30 ml/min per 1.73 m2 and
2.3% (95% CI: 1.1%–4.2%) of patients with eGFR $30

























Figure 1. Distribution of baseline hemoglobin and estimated glomerular filtration rate (eGFR) among patients in the cohort. Red diamonds
represent individuals who received a red blood cell transfusion after biopsy, black triangles represent those who were not transfused but
developed a hematoma postbiopsy, and blue boxes represent those in which neither of these events occurred. The vertical dotted line marks
the hemoglobin level of 10 g/dl and the horizontal dotted line marks the eGFR level of 30 ml/min per 1.73 m2.
Table 2. Association of clinical characteristics with need for
transfusion after biopsy, before and after adjustment for the
prebiopsy hemoglobin level (<10 vs. $10 g/dl)
CLINICAL RESEARCH R Palsson et al.: Bleeding Complications After Kidney Biopsypatient characteristics of interest with the need for
blood transfusion after biopsy. In univariable models,
blood transfusions were significantly associated with
baseline hemoglobin <10 g/dl (OR: 13.6; 95% CI: 5.4–
34.1), eGFR <30 ml/min per 1.73 m2 (OR: 3.9; 95% CI:
1.8–8.6), INR $1.1 (OR: 3.8; 95% CI: 1.7–8.7), wors-
ening renal function as the indication for biopsy (OR:
3.5; 95% CI: 1.6–7.7) and urgent inpatient biopsies
(OR: 6.3; 95% CI: 2.9–13.6). After adjusting for base-
line hemoglobin (<10 vs. $10 g/dl), however, none of
the other patient characteristics remained significantly
associated with postbiopsy transfusions, although ur-
gent inpatient biopsies remained nominally associated








Angiography followed by open surgery
Figure 2. Of 644 patients included in the analysis, 28 (4.3%) required
a red blood cell transfusion after undergoing percutaneous native
kidney biopsy; 4 (0.6%) required angiographic intervention and 1
(0.2%) subsequently underwent open surgery to control bleeding. No
patients lost a kidney or died because of the procedure.
514this, when the same patient characteristics were
entered together in a logistic regression model and an
automated stepwise selection procedure was utilized to
choose predictors, prebiopsy hemoglobin remained the
sole independent variable in the final model.
Hematomas visualized at the end of biopsy proced-
ures were nominally associated with the need for
subsequent RBC transfusion both before (OR: 2.14;
95% CI: 0.99–4.62; P ¼ 0.05) and after (OR: 2.00; 95%




<10 vs. ‡10 g/dl
OR (95% CI) P value OR (95% CI) P value
Age, per 10-yr increase 0.91 (0.73–1.13) 0.39 0.92 (0.73–1.15) 0.45
Female sex 1.27 (0.59–2.72) 0.55 0.98 (0.44–2.18) 0.96
Diabetes 2.18 (0.96–4.95) 0.06 1.49 (0.63–3.52) 0.37
Systolic blood pressure,
per 10 mm Hg increase
1.06 (0.86–1.30) 0.59 1.05 (0.86–1.29) 0.63
eGFR <30 ml/min
per 1.73 m2
3.89 (1.76–8.58) <0.01 1.55 (0.65–3.70) 0.33
Platelet count <150 K/ml 2.25 (0.82–6.16) 0.11 1.53 (0.53–4.43) 0.43
INR $1.1 3.82 (1.69–8.65) <0.01 1.89 (0.79–4.54) 0.16
Worsening eGFR as
indication for biopsy
3.48 (1.58–7.67) <0.01 1.82 (0.79–4.22) 0.16
Urgent inpatient procedure 6.27 (2.88–13.64) <0.01 2.13 (0.89–5.11) 0.09
Hemoglobin <10 g/dl 13.55 (5.38–34.12) <0.01 N/A N/A
CI, confidence interval; eGFR, estimated glomerular filtration rate; INR, international
normalized ratio; N/A, not applicable; OR, odds ratio.
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setting, the sensitivity and specificity of hematomas
were 42.9% and 74.0%, respectively. The positive
predictive value of hematomas was 7.0%, whereas the
negative predictive value was 96.6%.
Table 3 shows results of the post hoc analysis, where
we explored the association of the same patient char-
acteristics with decline in hemoglobin within 7 days
after biopsy. In univariable models, the factors signif-
icantly associated with decline in hemoglobin were
eGFR <30 ml/min per 1.73 m2 (b ¼ 0.16; 95% CI: 0.03–
0.30) and baseline hemoglobin (b ¼ 0.03; 95% CI: 0.00–
0.06 per g/dl increase). When all the variables of
interest were incorporated in a multivariable model,
female sex (b ¼ 0.18; 95% CI: 0.04–0.32), eGFR <30
ml/min per 1.73 m2 (b ¼ 0.32; 95% CI: 0.14–0.49) and
baseline hemoglobin (b ¼ 0.09; 95% CI: 0.05–0.13 per
g/dl increase) were independently associated with the
hemoglobin decline. The same 3 variables remained in
the final model when an automated stepwise selection
procedure was used. When the analysis was repeated
after multiple imputation for missing data or after
additional adjustment for the center at which the bi-
opsy took place, the results did not meaningfully
change (data not shown).
Table 4 shows associations of histopathologic lesions
with postbiopsy RBC transfusion. Although acute
tubular injury was significantly associated with trans-
fusion in a univariable model, it was no longer inde-
pendently associated with this outcome after
adjustment for prebiopsy hemoglobin (<10 vs. $10
g/dl). Interstitial fibrosis and tubular atrophy, global
glomerulosclerosis, arterial sclerosis, and arteriolar
sclerosis were not significantly associated with trans-
fusions in any of the corresponding univariable or
multivariable models. We did not find significant cor-




b coefficient 95% CI P value
Age, per 10-yr increase 0.02 0.02 to 0.05 0.44
Female sex 0.07 0.06 to 0.20 0.29
Diabetes 0.09 0.08 to 0.26 0.28
Systolic blood pressure, per 10 mm Hg increase 0.02 0.05 to 0.02 0.31
eGFR <30 ml/min per 1.73 m2 0.16 0.03 to 0.30 0.02
Platelet count <150 K/ml 0.05 0.27 to 0.17 0.66
INR $1.1 0.00 0.13 to 0.14 0.96
Worsening eGFR as indication for biopsy 0.06 0.07 to 0.19 0.37
Urgent inpatient biopsy 0.02 0.14 to 0.18 0.81
Baseline Hgb, per 1 g/dl increase 0.03 0.00 to 0.06 0.03
CI, confidence interval; eGFR, estimated glomerular filtration rate; Hgb, hemoglobin; INR, inter
aAll clinical characteristics of interest, shown in the table, were included in the model.
bAll clinical characteristics of interest, shown in the table, were included in the initial model
Kidney International Reports (2020) 5, 511–518lesions and postbiopsy hemoglobin decline. Consistent
with these findings, when adjusting for baseline he-
moglobin levels, we found no associations between
major clinicopathologic diagnostic categories and the
need for transfusion after biopsy (Table 5).DISCUSSION
Severe bleeding complications were relatively rare
(4.3%) in our cohort of patients undergoing percuta-
neous native kidney biopsy. Higher transfusion rates
were seen particularly among those with baseline he-
moglobin levels <10 g/dl or eGFR <30 ml/min per 1.73
m2. These findings may aid clinicians when discussing
the risk of kidney biopsy with individual patients and
obtaining their informed consent for the procedure.
The rates of severe complications were consistent
across the 2 hospitals included in our analysis, and fell
within ranges previously reported in the literature,
supporting the validity and generalizability of our
findings.11–17 Even though perinephric hematomas
were frequently visualized on imaging after biopsy and
the median drop in hemoglobin was 0.7 g/dl, patients
seldom required blood transfusions or invasive in-
terventions to control bleeding. No patients lost a
kidney or died because of the procedure.
Although several patient characteristics were asso-
ciated with the need for postbiopsy blood transfusion
in unadjusted analyses, we found that the risk of
transfusion was first and foremost driven by the he-
moglobin level before the procedure. Indeed, other
patient characteristics associated with transfusion
postbiopsy were correlated with baseline hemoglobin,
and after adjusting only for hemoglobin, they did not
remain independently associated with the need for
transfusion. Patients with higher baseline levels of




b coefficient 95% CI P value b coefficient 95% CI P value
0.00 0.04 to 0.04 0.89 – – –
0.18 0.04 to 0.32 0.01 0.17 0.04 to 0.31 0.01
0.10 0.08 to 0.27 0.29 – – –
0.03 0.04 to 0.04 0.89 – – –
0.32 0.14 to 0.49 <0.01 0.36 0.20 to 0.51 <0.01
0.00 0.22 to 0.22 0.97 – – –
0.03 0.12 to 0.19 0.70 – – –
0.07 0.08 to 0.22 0.35 – – –
0.01 0.18 to 0.19 0.94 – – –
0.09 0.05 to 0.13 <0.01 0.08 0.04 to 0.11 <0.01
national normalized ratio.
and an automated stepwise selection procedure was then used to choose predictors.
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OR (95% CI) P value OR (95% CI) P value
IFTA (>25%) 0.98 (0.45–2.12) 0.95 0.59 (0.26–1.35) 0.21
Global glomerulosclerosis
(>25%)
1.01 (0.46–2.23) 0.97 0.82 (0.36–1.87) 0.63
Arterial sclerosis (moderate
or severe vs. none or mild)
1.22 (0.55–2.68) 0.62 1.16 (0.51–2.64) 0.73
Arteriolar sclerosis (moderate
or severe vs. none or mild)
1.11 (0.52–2.38) 0.78 0.90 (0.41–2.00) 0.80
Acute tubular injury (moderate
or severe vs. none or mild)
3.76 (1.66–8.50) <0.01 1.46 (0.61–3.51) 0.40
CI, confidence interval; IFTA, interstitial fibrosis and tubular atrophy; OR, odds ratio.
CLINICAL RESEARCH R Palsson et al.: Bleeding Complications After Kidney Biopsyafter biopsy in absolute terms (i.e., g/dl) but were still
less likely to require transfusion. Although it has been
suggested that anemia may itself hamper hemostasis,18
our results in this regard mimic those of Whittier
et al.,19 who reported in a large prospective study that
anemia is a predictor of receiving a blood transfusion
after biopsy, but not of bleeding.
Hematomas were commonly visualized at the end of
biopsy procedures. Most were self-limited and incon-
sequential, as evidenced by their positive predictive
value of only 7% for RBC transfusions. Although we
found that their negative predictive value was high at
96.6%, this was primarily a result of the low rate of
blood transfusions. Sensitivity and specificity of post-
procedure hematomas for bleeding requiring trans-
fusion were notably both modest.Table 5. Association of clinicopathologic diagnostic categories with
need for transfusion after biopsy, before and after adjustment for










OR (95% CI) P value OR (95% CI) P value











































CI, confidence interval; GN, glomerulonephritis; N/A; not applicable; OR, odds ratio.
Five biopsies were nondiagnostic and not included in the table.
516Previous studies of the risk of bleeding complications
after kidney biopsy have commonly focused on blood
transfusions as we did in our primary analysis, because
this allows severe bleeding events to be broadly
captured, whether in the form of internal hematomas or
hematuria, and because transfusions are both clinically
relevant and can be readily adjudicated. Given how
infrequently transfusions are required after kidney bi-
opsy and the relatively modest size of most biopsy co-
horts, however, studies designed in this manner tend not
to be well powered to identify risk factors for excessive
bleeding. It is likely that the literature on this subject,
which contains multiple such observational studies,
each with a low number of events, may thus be sus-
ceptible to publication bias. A meta-analysis by Corapi
et al.17 summarized findings of 32 studies involving 9456
native kidney biopsies where erythrocyte transfusions
were examined as the outcome, and identified signifi-
cantly higher rates of transfusions after biopsy in
women, in patients with a serum creatinine>2 mg/dl, in
the setting of acute kidney injury, andwith use of larger-
gauge biopsy needles. Significant heterogeneity between
studies was noted and the possibility of publication bias
in this field was acknowledged, although funnel plots to
examine this for these individual risk factors for RBC
transfusion after biopsy were not shown.
Given the above limitations of blood transfusions as
a study outcome, we performed a post hoc analysis with
maximum decline in hemoglobin within a week after
biopsy as the outcome, to identify characteristics
associated with excessive bleeding after kidney biopsy
in a more sensitive manner. Interestingly, in this
analysis we found female sex and eGFR <30 ml/min per
1.73 m2 to be independent predictors of bleeding after
multivariable adjustment, similar to the aforemen-
tioned meta-analysis. Although it is possible that the
observed hemoglobin nadir would have been lower in
patients who received an RBC transfusion if this
intervention had not taken place, this potential bias
applied only to a small minority of the cohort. We
believe that this method, although not without limi-
tations, can thus be a useful adjunct in studies
exploring bleeding risk after kidney biopsy.
Patients with advanced kidney disease arewell known
to be at increased risk of bleeding. The pathophysiology
of uremic bleeding is incompletely understood, but
abnormal platelet function plays a major role.20,21
Decreased kidney function, both in the setting of
chronic kidney disease and acute kidney injury, has
accordingly been identified as a risk factor for bleeding
after kidney biopsy.16,22–25 Our data lend further support
to an association between kidney function and bleeding
risk after biopsy. Although desmopressin may decrease
the risk of bleeding when administered to patients withKidney International Reports (2020) 5, 511–518
R Palsson et al.: Bleeding Complications After Kidney Biopsy CLINICAL RESEARCHdecreased kidney function before invasive proced-
ures,26–28 we were unable to evaluate its effect in our
cohort because of missing data. Female sex has also
repeatedly been identified as a risk factor for bleeding
after kidney biopsy.15–17,29 It has been suggested previ-
ously that this association might be due to confounding
by the lower eGFR among women at a given serum
creatinine compared with men, as older studies have
commonly adjusted for renal function using serum
creatinine rather than eGFR. Interestingly, however, our
analysis again demonstrates increased risk amongwomen
despite adjustment for eGFR in our regression models. It
is possible that women are at increased risk of bleeding
due to the smaller size of their kidneys compared with
men’s, which might increase the chance of inadvertent
injury to deeper structures during the biopsy procedure.
Biopsies obtained in urgent settings among hospi-
talized patients have previously been associated with
increased risk of major bleeding events,30 and were
nominally associated with postbiopsy blood trans-
fusions in our analysis. Although it might be expected
that acutely ill hospitalized patients were at higher risk
of bleeding because of other associated risk factors,
such as recent exposure to thromboprophylactic
agents, we did not find them to have a larger drop in
hemoglobin, suggesting rather that the threshold to
transfuse patients in this setting after a given drop in
their blood counts might be lower.
Uncontrolled hypertension and coagulopathy have
long been viewed as major risk factors for bleeding
after kidney biopsy.15,16,29,31–36 Patients in our cohort
with severe hypertension, thrombocytopenia, or INR
elevation were therefore not biopsied without earlier
intervention to address such abnormalities. For
example, only 13 patients in our cohort had a platelet
count <100 K/ml, and although 3 of them received a
transfusion after biopsy, our study was underpowered
to appropriately examine the association of such severe
thrombocytopenia with bleeding events. Hence, even
though systolic blood pressure, thrombocytopenia, and
INR were not independent predictors of major bleeding
complications in our study, these results must be
interpreted with caution and should not extrapolated
to patients with more abnormal values.
Many forms of kidney disease have been associated
with increased risk of bleeding, including acute tubular
injury, amyloidosis, cast nephropathy, and hyperten-
sive renal disease.29,35,37,38 However, such findings have
not been consistent across studies. For example, a study
by Soares et al.39 attempted to verify the higher bleeding
risk of patients with amyloidosis using a cohort of 101
patients with and 188 patients without amyloidosis but
found no evidence of heightened risk. We also found no
increase in risk of bleeding among patients withKidney International Reports (2020) 5, 511–518paraprotein-associated kidney disease, and none of the
patients in our cohort with amyloidosis had a major
bleeding event postbiopsy. Although acute tubular
injury was associated with higher risk of transfusion
after biopsy in a univariable model, it was no longer
significant after covariate adjustment. We similarly
found no independently significant associations of other
histopathologic lesions or major categories of kidney
disease with bleeding.
Our study has several limitations. Because of its
retrospective observational design, residual confound-
ing is likely to be present. Certain covariates of interest,
such as biopsy needle gauge and the number of passes
made during the procedure, could not be included in this
analysis because of missing data.40 Our cohort derived
from 2 high-volume teaching hospitals in the same city
in the United States and results may not be generalizable
to smaller centers or those in different geographic loca-
tions. Importantly, although our cohort is large, major
bleeding events are quite rare and our power to detect
statistically significant risk factors is thus limited.
In summary, we found that the risk of major bleeding
complications after imaging guided percutaneous native
kidney biopsy at 2 Boston academic hospitals was 4.3%.
Anemia was the dominant risk factor for RBC trans-
fusion after biopsy. Patient characteristics indepen-
dently associated with a larger drop in hemoglobin after
biopsy, albeit with modest effect sizes, included female
sex, eGFR <30 ml/min per 1.73 m2, and higher baseline
hemoglobin. Exploratory analyses of changes in hemo-
globin after biopsy may serve a complementary role to
analyses of severe bleeding events and help further
define populations at risk for excessive bleeding.DISCLOSURE
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